- Home
- MGNX vs NPCT Comparison
MGNX vs NPCT Comparison
Compare MGNX & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NPCT
- Stock Information
- Founded
- MGNX 2000
- NPCT 2020
- Country
- MGNX United States
- NPCT United States
- Employees
- MGNX N/A
- NPCT N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- MGNX Health Care
- NPCT Finance
- Exchange
- MGNX Nasdaq
- NPCT Nasdaq
- Market Cap
- MGNX 257.3M
- NPCT 304.5M
- IPO Year
- MGNX 2013
- NPCT N/A
- Fundamental
- Price
- MGNX $3.23
- NPCT $10.47
- Analyst Decision
- MGNX Hold
- NPCT
- Analyst Count
- MGNX 10
- NPCT 0
- Target Price
- MGNX $7.17
- NPCT N/A
- AVG Volume (30 Days)
- MGNX 465.7K
- NPCT 107.1K
- Earning Date
- MGNX 11-05-2024
- NPCT 01-01-0001
- Dividend Yield
- MGNX N/A
- NPCT 9.82%
- EPS Growth
- MGNX N/A
- NPCT N/A
- EPS
- MGNX N/A
- NPCT N/A
- Revenue
- MGNX $141,329,000.00
- NPCT N/A
- Revenue This Year
- MGNX $174.73
- NPCT N/A
- Revenue Next Year
- MGNX N/A
- NPCT N/A
- P/E Ratio
- MGNX N/A
- NPCT N/A
- Revenue Growth
- MGNX 16.68
- NPCT N/A
- 52 Week Low
- MGNX $2.95
- NPCT $8.58
- 52 Week High
- MGNX $21.88
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- NPCT 22.30
- Support Level
- MGNX $3.10
- NPCT $11.25
- Resistance Level
- MGNX $3.30
- NPCT $10.64
- Average True Range (ATR)
- MGNX 0.19
- NPCT 0.16
- MACD
- MGNX 0.00
- NPCT -0.06
- Stochastic Oscillator
- MGNX 25.45
- NPCT 1.64
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.